Meiji Yasuda Asset Management Co Ltd. Sells 265 Shares of Edwards Lifesciences Co. (NYSE:EW)

Meiji Yasuda Asset Management Co Ltd. lessened its position in Edwards Lifesciences Co. (NYSE:EW) by 2.1% during the fourth quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The fund owned 12,486 shares of the medical research company’s stock after selling 265 shares during the period. Meiji Yasuda Asset Management Co Ltd.’s holdings in Edwards Lifesciences were worth $924,000 at the end of the most recent reporting period.

A number of other hedge funds have also recently modified their holdings of EW. Baxter Bros Inc. increased its holdings in Edwards Lifesciences by 3.0% during the 4th quarter. Baxter Bros Inc. now owns 87,824 shares of the medical research company’s stock valued at $6,502,000 after purchasing an additional 2,556 shares during the period. TIAA Trust National Association increased its stake in shares of Edwards Lifesciences by 6.4% during the fourth quarter. TIAA Trust National Association now owns 10,943 shares of the medical research company’s stock valued at $810,000 after buying an additional 656 shares during the period. Prudential Financial Inc. raised its holdings in shares of Edwards Lifesciences by 16.2% during the fourth quarter. Prudential Financial Inc. now owns 432,460 shares of the medical research company’s stock valued at $32,015,000 after acquiring an additional 60,171 shares in the last quarter. Crowley Wealth Management Inc. purchased a new stake in Edwards Lifesciences in the fourth quarter worth $26,000. Finally, Vanguard Group Inc. boosted its holdings in Edwards Lifesciences by 10.4% in the fourth quarter. Vanguard Group Inc. now owns 69,132,036 shares of the medical research company’s stock valued at $5,117,845,000 after acquiring an additional 6,537,494 shares in the last quarter. Hedge funds and other institutional investors own 79.46% of the company’s stock.

Edwards Lifesciences Trading Down 0.2 %

Edwards Lifesciences stock opened at $71.12 on Thursday. Edwards Lifesciences Co. has a one year low of $58.93 and a one year high of $96.12. The business’s fifty day moving average is $71.45 and its 200 day moving average is $70.45. The company has a debt-to-equity ratio of 0.06, a current ratio of 3.46 and a quick ratio of 2.89. The stock has a market capitalization of $41.81 billion, a PE ratio of 10.20, a price-to-earnings-growth ratio of 4.82 and a beta of 1.12.

Edwards Lifesciences (NYSE:EW) last announced its quarterly earnings results on Tuesday, February 11th. The medical research company reported $0.59 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.55 by $0.04. Edwards Lifesciences had a net margin of 72.93% and a return on equity of 19.40%. On average, sell-side analysts predict that Edwards Lifesciences Co. will post 2.45 EPS for the current year.

Analysts Set New Price Targets

EW has been the subject of several research analyst reports. Piper Sandler raised their target price on shares of Edwards Lifesciences from $70.00 to $73.00 and gave the stock a “neutral” rating in a research report on Wednesday, February 12th. Morgan Stanley upped their target price on Edwards Lifesciences from $70.00 to $75.00 and gave the stock an “equal weight” rating in a report on Wednesday, February 12th. Barclays increased their target price on Edwards Lifesciences from $88.00 to $90.00 and gave the stock an “overweight” rating in a research report on Thursday, February 13th. The Goldman Sachs Group upped their price target on Edwards Lifesciences from $81.00 to $90.00 and gave the stock a “buy” rating in a research note on Thursday, December 5th. Finally, Bank of America raised Edwards Lifesciences from a “neutral” rating to a “buy” rating and raised their price objective for the company from $82.00 to $90.00 in a research report on Monday, December 16th. One equities research analyst has rated the stock with a sell rating, fourteen have given a hold rating and eleven have assigned a buy rating to the company’s stock. According to data from MarketBeat, the company currently has an average rating of “Hold” and an average price target of $79.95.

Insiders Place Their Bets

In other Edwards Lifesciences news, CFO Scott B. Ullem sold 11,250 shares of the business’s stock in a transaction dated Wednesday, March 26th. The stock was sold at an average price of $70.87, for a total transaction of $797,287.50. Following the completion of the sale, the chief financial officer now directly owns 30,387 shares in the company, valued at $2,153,526.69. The trade was a 27.02 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, Director Steven R. Loranger sold 5,739 shares of the stock in a transaction that occurred on Friday, February 14th. The stock was sold at an average price of $76.42, for a total transaction of $438,574.38. Following the completion of the transaction, the director now owns 60,372 shares in the company, valued at $4,613,628.24. This trade represents a 8.68 % decrease in their position. The disclosure for this sale can be found here. In the last quarter, insiders sold 62,553 shares of company stock valued at $4,513,064. Company insiders own 1.29% of the company’s stock.

Edwards Lifesciences Company Profile

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband names.